{"id":"NCT00546572","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","officialTitle":"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2007-10-19","resultsPosted":"2011-05-30","lastUpdate":"2011-07-14"},"enrollment":938,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"13 valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"23vPS","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.","primaryOutcome":{"measure":"Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)","timeFrame":"1 month after Vax 1 / Year 0","effectByArm":[{"arm":"13vPnC","deltaMin":81,"sd":null},{"arm":"23vPS","deltaMin":55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"70 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":58,"countries":["United States","Sweden"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3005&StudyName=Study%20Evaluating%20The%20Safety%2C%20Tolerability%20And%20Immunogenicity%20Of%20A%2013-Valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":463},"commonTop":["Pain (Any)","Pain (Mild)","New generalized muscle pain","Fatigue","Pain (Any)"]}}